AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29231159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and psychological (CPP) programme
Number of subjects: 9
Study 25764523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (8 J/cm², 1064 nm, 60 sec, 0.5 W)
Number of subjects: 10
Study 25764523 — intervention group
Group type: COMPARATOR
Intervention: Control (no laser treatment)
Number of subjects: 10
Study 24073995 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 451
Study 24073995 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 451
Study 24073995 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 451
Study 24073995 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Sitagliptin
Number of subjects: 451
Study 24073995 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 451
Study 22996721 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct prior knowledge of walking terrain
Number of subjects: 9
Study 22996721 — intervention group
Group type: COMPARATOR
Intervention: Incorrect prior knowledge of walking terrain
Number of subjects: 9
Study 19541948 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise counseling (10 weeks, individually delivered)
Number of subjects: 60
Study 19541948 — intervention group
Group type: COMPARATOR
Intervention: Health education contact control (10 weeks)
Number of subjects: 60
Study 17334593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 40
Study 17334593 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study 17334593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40
Study 15125520 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily topical application of 1/3 diluted camphor oil with glycerol and 500 mg metronidazole orally for fifteen days
Number of subjects: 27
Study 15125520 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 females free from other dermatological lesions)
Number of subjects: 27
Study 11779901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg every 4 hours for 24 hours
Number of subjects: 39
Study 11779901 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 hours for 24 hours
Number of subjects: 39
Study 11779901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 39
Study 9640568 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine 1 hour before and immediately after surgery (group C)
Number of subjects: 51
Study 9640568 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine 1 hour before surgery (group B)
Number of subjects: 51
Study 9640568 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (group A)
Number of subjects: 51
Study 8074628 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4 mg.kg‐1
Number of subjects: 8
Study 8074628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2561141 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine twice a day
Number of subjects: 27
Study 2561141 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril once a day
Number of subjects: 27
Study 781835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine
Number of subjects: 34
Study 781835 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiphenesine
Number of subjects: 34
Study 781835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29635951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal iliac artery (IIA) ligation followed by caesarean hysterectomy
Number of subjects: 57
Study 29635951 — intervention group
Group type: COMPARATOR
Intervention: Control group (caesarean hysterectomy only)
Number of subjects: 57
Study 28004215 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (1-15 mg/day)
Number of subjects: 92
Study 28004215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 25970252 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) administered 1 hour before each of 5 exposure and response prevention tasks
Number of subjects: 128
Study 25970252 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 1 hour before each of 5 exposure and response prevention tasks
Number of subjects: 128
Study 25970252 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 128
Study 25970252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 23625077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical movements at three prescribed frequencies
Number of subjects: 0
Study 23625077 — intervention group
Group type: COMPARATOR
Intervention: Quasistatic conditions
Number of subjects: 0
Study 21091697 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for 16 weeks
Number of subjects: 116
Study 21091697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron substitution)
Number of subjects: 116
Study 19125674 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of Helicobacter pylori infection
Number of subjects: 219
Study 19125674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 219
Study 19125674 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative children
Number of subjects: 219
Study 17454420 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15342174 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 428
Study 15342174 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 428
Study 15342174 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control and Rhythm control
Number of subjects: 428
Study 11510809 — intervention group
Group type: EXPERIMENTAL
Intervention: FI,O2=0.3
Number of subjects: 10
Study 11510809 — intervention group
Group type: EXPERIMENTAL
Intervention: FI,O2=0.5
Number of subjects: 10
Study 9579296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 63
Study 9579296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 18800457 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg losartan
Number of subjects: 11
Study 18800457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2694856 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic selective flora suppression regimen consisting of polymyxin E, tobramycin and amphotericin B
Number of subjects: 200
Study 2694856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 409592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamically oriented psychotherapy for over one year
Number of subjects: 20
Study 409592 — intervention group
Group type: COMPARATOR
Intervention: Therapist randomly assigned (Clinic staff member or senior resident in psychiatry)
Number of subjects: 20
Study 31405721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial injury (n = 124)
Number of subjects: 239
Study 31405721 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 115)
Number of subjects: 239
Study 28453838 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivalent GI.1 and GII.4c norovirus VLP vaccine candidate adjuvanted with alum and MPL
Number of subjects: 0
Study 26515660 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue donepezil without memantine
Number of subjects: 295
Study 26515660 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue donepezil without memantine
Number of subjects: 295
Study 26515660 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue donepezil and start memantine
Number of subjects: 295
Study 26515660 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue donepezil and start memantine
Number of subjects: 295
Study 26515660 — intervention group
Group type: COMPARATOR
Intervention: Combined donepezil discontinuation groups
Number of subjects: 295
Study 26515660 — intervention group
Group type: COMPARATOR
Intervention: Combined donepezil continuation groups
Number of subjects: 295
Study 26515660 — intervention group
Group type: COMPARATOR
Intervention: Starting memantine
Number of subjects: 295
Study 22834862 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic endoscope holder
Number of subjects: 20
Study 21076285 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioemotional stress condition
Number of subjects: 19
Study 21076285 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without socioemotional stress)
Number of subjects: 19
Study 18663402 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of ibandronate (ACE doses > or = 10.8 mg: 150 mg once monthly, 3 mg i.v. quarterly, 2 mg i.v. every 2 months)
Number of subjects: 8
Study 18663402 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of ibandronate (ACE doses of 5.5 mg)
Number of subjects: 8
Study 18663402 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE doses of 7.2‐12 mg
Number of subjects: 8
Study 16708044 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nursing intervention
Number of subjects: 121
Study 16708044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 16708044 — intervention group
Group type: COMPARATOR
Intervention: Posttest-only comparison group
Number of subjects: 121
Study 15028347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative procedures (coronary atherectomy, laser angioplasty, cutting balloon atherotomy)
Number of subjects: 9222
Study 15028852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 90
Study 15028852 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 90
Study 10679645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 30 mg intramuscularly every 10 days for 1 month
Number of subjects: 33
Study 10679645 — intervention group
Group type: COMPARATOR
Intervention: Octreotide 200 microg subcutaneously twice or thrice daily for 1 month
Number of subjects: 33
Study 10679645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide and octreotide
Number of subjects: 33
Study 10679645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 33
Study 10679645 — intervention group
Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 33
Study 9357942 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem, middle latency, and cortical auditory evoked responses (BMC‐AERs)
Number of subjects: 81
Study 8404404 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (2 g daily)
Number of subjects: 101
Study 8404404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 3090849 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser conization
Number of subjects: 123
Study 3090849 — intervention group
Group type: COMPARATOR
Intervention: Cold knife conization
Number of subjects: 123
Study 2688972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 150
Study 2688972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 30651059 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call and text message intervention provided by trained nurses.
Number of subjects: 120
Study 30651059 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 120
Study 28493741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45g/kg alcohol dose in activational condition
Number of subjects: 40
Study 28493741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65g/kg alcohol dose in activational condition
Number of subjects: 40
Study 28493741 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in activational condition
Number of subjects: 40
Study 28493741 — intervention group
Group type: COMPARATOR
Intervention: 0.45g/kg alcohol dose in inhibitory condition
Number of subjects: 40
Study 28493741 — intervention group
Group type: COMPARATOR
Intervention: 0.65g/kg alcohol dose in inhibitory condition
Number of subjects: 40
Study 28493741 — intervention group
Group type: COMPARATOR
Intervention: Placebo in inhibitory condition
Number of subjects: 40
Study 29400027 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-CliP® piston
Number of subjects: 20
Study 29400027 — intervention group
Group type: COMPARATOR
Intervention: Causse® Teflon prosthesis
Number of subjects: 20
Study 23283838 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 250 mg
Number of subjects: 0
Study 23283838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21550760 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) reconstruction
Number of subjects: 55
Study 21550760 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) single-bundle reconstruction
Number of subjects: 55
Study 21550760 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral (PL) single-bundle reconstruction
Number of subjects: 55
Study 21550760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysholm score
Number of subjects: 55
Study 21550760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegner score
Number of subjects: 55
Study 21550760 — intervention group
Group type: EXPERIMENTAL
Intervention: KT-1000 arthrometer
Number of subjects: 55
Study 21550760 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual pivot-shift test
Number of subjects: 55
Study 21550760 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength (knee extensor and flexor isokinetic peak torques at 60°/s)
Number of subjects: 55
Study 19633577 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 6.75 g/day
Number of subjects: 68
Study 19633577 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 2.25 g/day
Number of subjects: 68
Study 17597253 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating a piece of chocolate
Number of subjects: 161
Study 17597253 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating palatable chocolate
Number of subjects: 161
Study 17597253 — intervention group
Group type: COMPARATOR
Intervention: Drinking water
Number of subjects: 161
Study 17597253 — intervention group
Group type: COMPARATOR
Intervention: Eating unpalatable chocolate
Number of subjects: 161
Study 15531051 — intervention group
Group type: COMPARATOR
Intervention: Grip-measuring device with different shaped end-objects; tracking tasks including ramp-tracking and sinus-tracking.
Number of subjects: 29
Study 15531051 — intervention group
Group type: COMPARATOR
Intervention: Ramp-tracking task
Number of subjects: 29
Study 15531051 — intervention group
Group type: COMPARATOR
Intervention: Sinus-tracking task
Number of subjects: 29
Study 11421842 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 1 ml kg(‐1)
Number of subjects: 60
Study 11421842 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1 ml kg(‐1) + Tramadol 1.5 mg kg(‐1)
Number of subjects: 60
Study 11421842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg kg(‐1)
Number of subjects: 60
Study 9735661 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic subjects
Number of subjects: 20
Study 9735661 — intervention group
Group type: COMPARATOR
Intervention: Non-atopic subjects
Number of subjects: 20
Study 7983115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight plaster cast during the first three weeks
Number of subjects: 23
Study 7983115 — intervention group
Group type: COMPARATOR
Intervention: Patients without algodystrophy
Number of subjects: 23
Study 2695178 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy‐Co‐60 single dose of TBI plus 120 mg/kg of cyclophosphamide over 2 days (Group A)
Number of subjects: 2
Study 2695178 — intervention group
Group type: COMPARATOR
Intervention: 12 Gy Co‐60 of TBI in 6 fractions (2/day) plus 120 mg/kg of cyclophosphamide over 3 days (Group B)
Number of subjects: 2
Study 2695178 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 2
Study 2695178 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 2
Study 4441827 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight)
Number of subjects: 80
Study 30948595 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 92
Study 30948595 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 92
Study 28961595 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased mastery over 28 weeks
Number of subjects: 70
Study 28961595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mastery
Number of subjects: 70
Study 28961595 — intervention group
Group type: EXPERIMENTAL
Intervention: High mastery
Number of subjects: 70
Study 24856364 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy
Number of subjects: 65
Study 24856364 — intervention group
Group type: COMPARATOR
Intervention: Modified PE with imagery rescripting
Number of subjects: 65
Study 23399113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation with maintenance (RHBM group)
Number of subjects: 97
Study 23399113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation without maintenance (RHB group)
Number of subjects: 97
Study 23399113 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 97
Study 23399113 — intervention group
Group type: EXPERIMENTAL
Intervention: RHBM group
Number of subjects: 97
Study 23399113 — intervention group
Group type: EXPERIMENTAL
Intervention: RHB group
Number of subjects: 97
Study 23399113 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 22174748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 545
Study 22174748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study 19855847 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of MSP3-LSP
Number of subjects: 45
Study 19855847 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg of MSP3-LSP
Number of subjects: 45
Study 19855847 — intervention group
Group type: COMPARATOR
Intervention: Engerix B hepatitis B vaccine
Number of subjects: 45
Study 17112442 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (9 g)
Number of subjects: 11
Study 17112442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 11
Study 15043655 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles from Japan
Number of subjects: 20189
Study 15043655 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 20189
Study 15043655 — intervention group
Group type: EXPERIMENTAL
Intervention: Trend in Japan's contribution
Number of subjects: 20189
Study 11567820 — intervention group
Group type: EXPERIMENTAL
Intervention: One isocenter radiosurgery (n = 44)
Number of subjects: 87
Study 11567820 — intervention group
Group type: EXPERIMENTAL
Intervention: Two isocenter radiosurgery (n = 43)
Number of subjects: 87
Study 11567820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (one and two isocenters)
Number of subjects: 87
Study 9747366 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 50
Study 9747366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7921908 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of glucose in 300 ml of water (G trial)
Number of subjects: 9
Study 7921908 — intervention group
Group type: COMPARATOR
Intervention: 300 ml of sweetened water (P trial)
Number of subjects: 9
Study 3202370 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sustained-release theophylline preparation
Number of subjects: 16
Study 3202370 — intervention group
Group type: COMPARATOR
Intervention: Placebo sustained-release theophylline preparation
Number of subjects: 16
Study 31597020 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster increment (30 ml/kg/day)
Number of subjects: 2804
Study 31597020 — intervention group
Group type: COMPARATOR
Intervention: Slower increment (18 ml/kg/day)
Number of subjects: 2804
Study 28929940 — intervention group
Group type: EXPERIMENTAL
Intervention: GGWB program (yoga-based prevention program)
Number of subjects: 0
Study 28929940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25728587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab and azathioprine)
Number of subjects: 188
Study 24907494 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 30
Study 24907494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21962336 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal-psychotherapy-oriented childbirth education programme
Number of subjects: 194
Study 21962336 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 194
Study 19660005 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg single dose
Number of subjects: 0
Study 19660005 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg multiple doses (twice daily for 6 days)
Number of subjects: 0
Study 19660005 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (various doses: 2.5, 5, 10, 20, 40 mg single dose; 5, 10, 20, 30 mg multiple doses)
Number of subjects: 0
Study 17451422 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 17451422 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 0
Study 17451422 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol vs Metoprolol tartrate
Number of subjects: 0
Study 15021281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 66
Study 15021281 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 66
Study 11549430 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hormonal therapy with LHRH analogue plus radiotherapy (COMB)
Number of subjects: 90
Study 11549430 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 90
Study 9820373 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/d for 6 months)
Number of subjects: 36